Children in the study receive eye drops in a single-dose container and are followed over several months. During the study, eye health, vision, eye comfort, and possible side effects are checked at different visits and by phone calls. The study also looks at changes in the length of the eye, which can increase as myopia gets worse, as well as other eye findings such as redness, eye surface irritation, eye pressure, and the condition of the cornea, which is the clear front part of the eye.

The trial compares T10430 with placebo to learn more about safety and possible benefit. The treatment is given to both eyes, and the study follows participants for about one year.

The research involves children aged 6 to 14 years who have myopia of at least -1.50 diopters (a unit of measurement for the focusing power of the eye). During the study, participants will receive brimonidine eye drops, and their eye measurements will be taken every six months to track any changes in their vision. These measurements include the axial length (the distance from the front to the back of the eye), visual acuity (sharpness of vision), and other eye characteristics.

The study will monitor various aspects of eye health including pupillometry (measurement of pupil size under different lighting conditions), accommodation (how well the eye adjusts focus), corneal topography (mapping the surface curvature of the cornea), and intraocular pressure (pressure inside the eye). Throughout the study, safety will be assessed by collecting information about any adverse events.

The study involves using eye drops containing atropine sulfate monohydrate or placebo. Participants will need to use the eye drops daily for 24 months. The drops are specifically designed for children and will be administered directly into the eyes. Each participant will receive two drops per day throughout the treatment period.

The purpose of this research is to determine if atropine eye drops can slow down the progression of myopia in young people between 3 and 18 years of age. During the study, doctors will regularly check how the participants’ vision changes by measuring their eye prescription and performing various vision tests. The study will track how well the different strengths of atropine work in preventing myopia from getting worse compared to the placebo treatment.

The purpose of this study is to determine how well these eye drops work in slowing down the progression of myopia in children over a three-year treatment period. The study will compare the effectiveness of OT-101 eye drops against a placebo solution that looks the same but contains no active medication.

During the study, participants will receive either the OT-101 eye drops or placebo drops. The drops will be administered through ophthalmic use (placed directly in the eyes). The treatment will continue for three years, with regular check-ups to monitor changes in vision. The study will measure how the eye drops affect the progression of nearsightedness using specialized eye examinations.

The purpose of the study is to determine how well this combination treatment works in slowing down the worsening of myopia in children. Participants in the study will use the atropine eye drops, which are applied as one drop per day, and wear the DIMS lenses. The study will monitor changes in the participants’ vision over time to see if the treatment helps in controlling myopia progression. The study will also keep track of any side effects that may occur during the treatment period.

The study will take place over a period of time, and participants will be regularly checked to assess their vision and eye health. This will include measuring changes in their eyesight and examining the thickness of certain parts of the eye using a method called Optical Coherence Tomography (OCT). The study aims to provide valuable information on whether this treatment can be a safe and effective option for managing myopia in children.

The study aims to determine which concentration of the eye drops works better in European children who have progressive myopia. Children in the study will receive either the stronger (0.5%) or weaker (0.05%) version of the eye drops. The treatment will continue for several years to understand how well each concentration works in preventing the condition from getting worse.

During the study, doctors will monitor changes in children’s vision and eye health. They will also look at how safe the different concentrations are, how well children follow the treatment plan, and what happens after the treatment ends. The eye drops will be given daily, and regular check-ups will help track the children’s eye health throughout the study period.

The purpose of the study is to determine the most effective dose of atropine sulfate eye drops for reducing the progression of myopia in children. Participants in the study will receive one of the different doses of atropine sulfate eye drops or a placebo. The study will last for about a year, during which the children will have regular check-ups to monitor changes in their vision and eye health. These check-ups will include measuring the growth of the eye, the depth of the front part of the eye, and other aspects of eye function.

Throughout the study, the safety of the atropine sulfate eye drops will be closely monitored. This includes checking for any side effects that might occur in the eyes or elsewhere in the body. The study will also look at how the eye drops affect different eye colors, as well as any changes in vision clarity and eye pressure. The goal is to ensure that the treatment is both effective and safe for children with myopia.

The purpose of the study is to determine if these eye drops can effectively slow the growth of the eye, which is a key factor in the progression of myopia. Children participating in the study will use the eye drops daily over a period of up to two years. During this time, they will have regular check-ups every six months to monitor changes in their vision and eye health. The study will also look at any side effects that might occur from using the eye drops.

Throughout the study, researchers will measure changes in the length of the eye, known as axial eye length, and other aspects of eye health. The study aims to provide valuable information on whether these low-dose atropine eye drops can be a safe and effective treatment option for children with myopia, potentially helping to manage this common vision problem more effectively.

Participants in the study will be randomly assigned to receive either the SYD-101 eye drops or a similar solution that does not contain the active drug, known as a placebo. The study is designed to be “double-masked,” meaning that neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations. The treatment period will last for up to 48 months, during which participants will use the eye drops daily.

Throughout the study, participants will have regular check-ups to monitor the progression of their myopia and to check for any side effects. The main goal is to see if the use of SYD-101 can reduce the rate at which myopia worsens over time. The study will also gather information on any changes in vision and overall eye health. This research aims to provide valuable insights into managing myopia in children and potentially improving their quality of life by preserving their vision.

The purpose of the study is to determine if the 0.02% dose of Atropine Sulfate is more effective than a placebo in slowing down the worsening of myopia in children of Caucasian origin. The study will last for one year, during which the changes in the children’s vision will be monitored. The children participating in the study will receive either the 0.02% atropine eye drops, the 0.01% atropine eye drops, or a placebo.

Throughout the study, the main focus will be on measuring how much the children’s vision changes over the year. This will be done by checking the change in their eye prescription, known as cycloplegic refraction, and the length of their eyes. The study aims to provide valuable information on whether low-dose Atropine Sulfate can effectively control myopia progression in children.